Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Epcoritamab + Lenalidomide + Rituximab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Epcoritamab||DuoBody-CD3xCD20|GEN 3013|GEN-3013|GEN3013||CD20 Antibody 17 CD3 Antibody 63||Epcoritamab (GEN3013) is a bispecific antibody that targets CD3 and CD20, resulting in T-cell activation and redirection of T-cells to CD20-expressing tumor cells, which may lead to tumor cell cytotoxicity and inhibition of tumor growth (PMID: 31981978, PMID: 33602901).|
|Lenalidomide||Revlimid||IMiD-1||Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov).|
|Rituximab||Rituxan||IDEC-C2B8|MabThera||CD20 Antibody 17||Rituxan (rituximab) is a chimeric mononclonal antibody that binds to CD20 on B-cells, resulting in induction of complement-dependent and antibody-dependent cytotoxicity, and potentially leading to decreased B-cell tumor growth (PMID: 28983798). Rituxan (rituximab) is FDA approved for use as monotherapy or in combination with chemotherapy in CD20-positive B-cell non-Hodgkin lymphoma, in combination with fludarabine and cyclophosphamide in CD20-positive chronic lymphocytic leukemia, and in combination with chemotherapy in pediatric patients (6 month to 18 years of age) with treatment-naive, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia (B-AL) (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05409066||Phase III||Lenalidomide + Rituximab Epcoritamab + Lenalidomide + Rituximab||Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)||Recruiting||USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT||22|
|NCT04663347||Phase Ib/II||Cisplatin + Cytarabine + Dexamethasone + Epcoritamab + Rituximab Epcoritamab + Gemcitabine + Oxaliplatin Epcoritamab + Lenalidomide + Rituximab Bendamustine + Epcoritamab + Rituximab Cyclophosphamide + Doxorubicin + Epcoritamab + Prednisone + Rituximab + Vincristine Sulfate||Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma||Recruiting||USA | ITA | FRA | ESP | BEL||8|